Site icon LucidQuest Ventures

Hematology Weekly News – March 17th 2025

Hematology

Hematology

πŸš€ Hematology News: Advancements inΒ  blood cancers, acute and chronic leukemias, multiple myeloma, iron deficiency anemia, polycythemia vera, and transfusion-dependent anemia.

From new CAR-T breakthroughs to enhanced minimal residual disease detection, these updates are shaping the future of hematologic and rare blood disorders.

πŸ©ΈπŸ”¬ πŸ“° Key Headlines & Updates:

πŸ’‰ FDA Approves Brentuximab Combo for Difficult-to-Treat Large B-Cell Cancer

🧬 Cema-cel Shows Promising Response as an Off-the-Shelf CAR-T for Large B-Cell Cancer

🩸 clonoSEQ Assay Now More Sensitive for Detecting Minimal Residual Disease in Blood Cancers

🌏 Indonesia Approves Selinexor for Multiple Myeloma and Large B-Cell Cancer

🎯 Next-Generation Anti-CD38 CAR-T Therapy Shows Strong Potential for Treating Myeloma

❌ J&J and Genmab Discontinue Development of Next-Gen CD38 Antibody for Myeloma πŸ‡°πŸ‡· Korean Authorities Approve Blincyto as a New Consolidation Therapy for Acute Lymphoblastic Leukemia

πŸ’Š BOVen Regimen Shows High Efficacy in Patients with TP53-Mutated Blood Cancer

πŸ† Acalabrutinib-Based Treatment Demonstrates Long-Term Benefits in Frontline and Relapsed Blood Cancers

🌏 Breakthrough Therapy Designation in China for Olverembatinib in Philadelphia Chromosome-Positive Blood Cancer

πŸ’° Ono and Ionis Ink $900 Million Deal for Sapablursen, a New RNA Therapy for Polycythemia Vera πŸ‡¨πŸ‡¦ ACCRUFeR Now Available in Canada as a Prescription Treatment for Iron Deficiency Anemia

πŸ₯ European Commission Grants Approval to Rytelo for Treating Transfusion-Dependent Anemia

πŸ“’ Stay ahead in hematology research!

βœ… Like, share, and subscribe for weekly updates.

#Hematology #BloodCancer #CAR-T #Leukemia #MultipleMyeloma #Anemia #MedicalBreakthroughs #ClinicalResearch #LucidQuest #HealthcareInnovation

Exit mobile version